During the past decade, The Catholic University of Korea, Seoul St.Mary's Hospital conducted 550 clinical trials. In the 10-year time frame, 550 clinical trials started and 149 clinical trials were completed, i.e. on average, 27.1% percent of trials that started reached the finish line to date. In the past 5 years, 263 clinical trials started and 101 clinical trials were completed. i.e. 38.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Catholic University of Korea, Seoul St.Mary's Hospital" #1 sponsor was "The Catholic University of Korea" with 47 trials, followed by "Hoffmann-La Roche" with 35 trials sponsored, "Janssen Research & Development, LLC" with 33 trials sponsored, "Seoul St. Mary's Hospital" with 33 trials sponsored and "Pfizer" with 33 trials sponsored. Other sponsors include 601 different institutions and companies that sponsored additional 259 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Catholic University of Korea, Seoul St.Mary's Hospital" #1 collaborator was "CardioVascular Research Foundation, Korea" with 32 trials as a collaborator, "Seoul St. Mary's Hospital" with 16 trials as a collaborator, "The Catholic University of Korea" with 13 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 11 trials as a collaborator and "AstraZeneca" with 9 trials as a collaborator. Other collaborators include 373 different institutions and companies that were collaborators in the rest 234 trials.

According to Clinical.Site data, the most researched conditions in "The Catholic University of Korea, Seoul St.Mary's Hospital" are "Coronary Artery Disease" (31 trials), "Multiple Myeloma" (23 trials), "Gastric Cancer" (18 trials), "Hypertension" (14 trials) and "Atrial Fibrillation" (12 trials). Many other conditions were trialed in "The Catholic University of Korea, Seoul St.Mary's Hospital" in a lesser frequency.

Most popular intervention types in "The Catholic University of Korea, Seoul St.Mary's Hospital" are "Drug" (575 trials), "Device" (72 trials), "Biological" (60 trials), "Other" (58 trials) and "Procedure" (42 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (121 trials), "Paclitaxel" (18 trials), "Carboplatin" (17 trials), "Cisplatin" (15 trials) and "Dexamethasone" (13 trials). Other intervention names were less common.

The vast majority of trials in "The Catholic University of Korea, Seoul St.Mary's Hospital" are 713 trials for "All" genders, 39 trials for "Female" genders and 31 trials for "Male" genders.

Currently, there are 282 active trials in "The Catholic University of Korea, Seoul St.Mary's Hospital". 4 are not yet recruiting, 163 are recruiting, 114 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 346 completed trials in The Catholic University of Korea, Seoul St.Mary's Hospital, undefined suspended trials, and 45 terminated clinical trials to date.

Out of the total trials that were conducted in The Catholic University of Korea, Seoul St.Mary's Hospital, 83 "Phase 1" clinical trials were conducted, 162 "Phase 2" clinical trials and 301 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 90 trials, and there were also 92 trials that are defined as “Not Applicable".